News Search Results
May 30, 2024, 14:55 ET Contract Research Organization (CRO) Market size is set to grow by USD 63.35 billion from 2024-2028, Growth of biopharmaceutical industry boost the market, Technavio
sponsored by key players or governments. In December 2022, Parexel announced a referral agreement with MyEyeDr. for ophthalmology clinical trials, expanding into endocrinology. Such collaborations accelerate drug development and contribute to market growth during the forecast
More news about: Technavio
May 30, 2024, 10:31 ET VNA & PACS Market to be Worth $6.50 Billion by 2031 - Exclusive Report by Meticulous Research®
PACSDental PACSOther Departmental PACSEnterprise PACSNote: Other departmental PACS include pathology, ophthalmology, and orthopedics PACS. PACS Market Assessment —by Delivery Mode On-Premise PACSWeb/Cloud-Based
More news about: Meticulous Market Research Pvt. Ltd.
May 30, 2024, 09:00 ET ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care
proven to increase efficiencies and improve patient outcomes," 1 says Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "Our expansive CIRRUS 6000 reference database provides
More news about: Carl Zeiss Meditec AG
May 30, 2024, 09:00 ET ZEISS announces OCT technology enhancements to better support growing era of data-driven patient care
proven to increase efficiencies and improve patient outcomes," 1 says Euan S. Thomson, Ph.D., President of Ophthalmology Strategic Business Unit and Head of the Digital Business Unit for ZEISS Medical Technology. "Our expansive CIRRUS 6000 reference database provides
More news about: Carl Zeiss Meditec AG
May 30, 2024, 04:00 ET NTC gives long term consistency to its ophtha portfolio with another MDR CE Certificate approval
/PRNewswire/ -- NTC, an International pharmaceutical company with headquarter in Italy, with a specific focus in ophthalmology and with a significant portfolio in gynecology and gastroenterology too, continues in its certification path and receives the fifth Medical Device
More news about: NTC Pharma
May 29, 2024, 16:36 ET Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
InflammationTime: 7:49 – 7:53 AM MTPresenter: Quan Dong Nguyen, M.D., Professor of Ophthalmology and Director of Uveitis and Ocular Inflammation, Byers Eye Institute, Stanford University School of Medicine.Title:
More news about: Kodiak Sciences Inc.
May 29, 2024, 09:00 ET FundamentalVR Revolutionizes Surgical Training with Advanced AI Capabilities
training and elevating performance standards globally. Selected as a partner by or accredited by leading institutions such as the American Academy of Ophthalmology, American Academy of Orthopaedic Surgeons, and the Royal College of Surgeons of England,
More news about: FundamentalVR
May 28, 2024, 10:00 ET Tarsier Pharma Announces the Appointment of Emilee Fulcher as Vice President of Clinical Affairs
invaluable asset to the team". Emilee has 20 years of experience in the pharmaceutical industry with a specialized background in executing ophthalmology clinical trials. Prior to joining Tarsier, Emilee was one of the first employees of Lexitas, an ophthalmic-focused CRO. During her 11-year tenure
More news about: Tarsier Pharma
May 28, 2024, 07:00 ET Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies, Inc.
May 28, 2024, 07:00 ET Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies
company is completing pre-clinical research on tailored therapies targeting indications in dermatology and immunology, and developing therapies for ophthalmology, osteo-arthritis, and the muscular system. For more information, see
More news about: Turn Biotechnologies, Inc.
May 28, 2024, 07:00 ET HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
endocrine, circulatory, and urologic diseases for over 50 years. HanAll has also expanded its focus to immunology, oncology, neurology, and ophthalmology to discover and develop innovative medicines for patients with diseases for which there are no effective treatments. One of its lead pipeline asset,
More news about: HanAll Biopharma
May 23, 2024, 10:01 ET Global Ambulatory Surgical Centers Market is Projected to Boost at a Moderate Growth Rate of ~6% by 2030 | DelveInsight
(Single-Specialty Centers and Multi-Specialty Centers)Ambulatory Surgical Centers Market Segmentation By Application: Gastroenterology, Ophthalmology, Orthopedics, Pain/Neurology, Urology, DermatologyAmbulatory Surgical Centers Market Segmentation By Geography: North
More news about: DelveInsight Business Research, LLP
May 23, 2024, 10:00 ET MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
procedures wherever needed. Its portability makes it ideal for a wide range of applications, including microsurgery, plastic surgery, dental procedures, ophthalmology, hair transplant surgery, and dermatology. The benefits of the SCOPEYE 3D Micro Surgery Solution are manifold. With high-resolution 3D optics,
More news about: VentureBlick
May 23, 2024, 08:10 ET Taro Shareholders Approve Merger with Sun Pharma
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
May 23, 2024, 07:50 ET Taro Shareholders Approve Merger with Sun Pharma
generic company in the US as well as Global Emerging Markets. Sun's high growth Global Specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
May 23, 2024, 06:00 ET NTC Ophthalmics lberica: Young ophthalmologists square in Zahara Los Atunes
"A career in Ophthalmology can follow different paths and it is important to give young people the chance to learn about the different ways their professional life can take",
More news about: NTC Ophthalmics lberica
May 23, 2024, 04:00 ET MediThinQ Unveils SCOPEYE 3D Micro Surgery Solution; Chris Lee of VentureBlick Assumes Chairmanship
procedures wherever needed. Its portability makes it ideal for a wide range of applications, including microsurgery, plastic surgery, dental procedures, ophthalmology, hair transplant surgery, and dermatology. The benefits of the SCOPEYE 3D Micro Surgery Solution are manifold. With high-resolution 3D optics,
More news about: VentureBlick
May 22, 2024, 20:51 ET PharmAbcine's U.S. Subsidiary, Wincal Biopharm, Presented Preclinical Data on Eye Drops from its Proprietary OPC Platform at ARVO 2024
announced that its U.S. subsidiary, Wincal Biopharm, Inc. ("WincalBio"), gained agreat attention at the world's largest ophthalmology conference, Association for Research in Vision and Ophthalmology 2024 (ARVO 2024), when they presented the preclinical data of the eye drop formulation.
More news about: PharmAbcine
May 22, 2024, 06:30 ET Global General Surgery Devices Market Size to Worth USD 30.33 Bn By 2031
increase in the adoption of minimally invasive surgery instruments across various surgical specialties such as orthopedic surgery, cardiology, ophthalmology, and neurosurgery. As a result, the segment of minimally invasive surgery instruments is expected to witness significant growth
More news about: Coherent Market Insights
May 21, 2024, 08:00 ET Biocon Biologics Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili™. Enters U.S. Ophthalmology Market
interchangeable* biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat several different types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept).
More news about: Biocon Biologics Ltd.
May 21, 2024, 07:00 ET Clario partners with Emsere to extend ophthalmic medical imaging capabilities for clinical trials
software platform. Clario and Emsere partner to provide an end-to-end medical imaging solution for ophthalmology clinical trials.Emsere specializes in providing sites with state-of-the-art ophthalmic equipment in a wide range of modalities.Strategic
More news about: Clario
May 21, 2024, 07:00 ET Clario partners with Emsere to extend ophthalmic medical imaging capabilities for clinical trials
software platform. Clario and Emsere partner to provide an end-to-end medical imaging solution for ophthalmology clinical trials.Emsere specializes in providing sites with state-of-the-art ophthalmic equipment in a wide range of modalities.Strategic
More news about: Clario
May 20, 2024, 20:51 ET Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
Diseases, Chinese Ophthalmology Branch, Chinese Medical Association; Group of Thyroid Diseases, Chinese Endocrinology Branch, Chinese Medical Association. Chinese Guidelines for the Diagnosis and Treatment of Thyroid Associated Ophthalmopathy (2022). Chinese Journal of Ophthalmology. 2022; 58 (9).
More news about: Innovent Biologics
May 20, 2024, 20:51 ET 信達生物宣布替妥尤單抗（IGF-1R抗體）新藥上市申請獲國家藥品監督管理局正式受理, 用於治療甲狀腺眼病
what is new to know? Curr Opin Ophthalmol. 2018;29(6):528-534.2. Bartley G. The epidemiological characteristics and clinical course of ophthalmology associated with autoimmune thyroid disease in Olmsted Country, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588.3.
More news about: 信達生物
May 19, 2024, 20:14 ET Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the company will deliver oral presentations on clinical data of its first-in-class PD-1/IL-2 bispecific
More news about: Innovent Biologics